Research progress of urinary bladder tumor markers

doi:10.3760/cma.j.issn.1007-1245.2022.20.018

Abstract

Abstract: Bladder cancer (BC) is one of the common malignant tumors of the urinary system, including non-muscular invasive bladder cancer (NMIBC) and muscular invasive bladder cancer (MIBC). At present, the clinical diagnosis of BC mainly depends on cystoscopy and urine cytology. With the needs of clinical practice and the progress of scientific research, how to achieve non-invasive diagnosis of BC through urine composition analysis has gradually become a research hotspot. At present, some urine markers have been approved for clinical use, but they have not been formally recommended by clinical guidelines due to various limitations, including many urine biomarkers that are still in the research stage, such as DNA methylation, microsatellite analysis, miRNA, and so on. This article reviews the current research progress of urinary bladder tumor markers.

Key words: Bladder cancer, Urine tumor markers, DNA methylation, miRNA, Microsatellite analysis

摘要： 膀胱癌是泌尿系统常见的恶性肿瘤之一，包括非肌层浸润性膀胱癌（non-muscular invasive bladder cancer，NMIBC）和肌层浸润性膀胱癌（muscular invasive bladder cancer，MIBC）。目前临床上主要依赖膀胱镜检查和尿细胞学检查来诊断膀胱癌，随着临床实践需要和科研进步，如何通过尿液成分分析来实现膀胱癌的无创性诊断逐渐成为研究热点。现阶段已有一些尿液标志物被批准应用于临床，但因各种局限性均未得到临床指南的正式推荐，当然也包括很多尚处于研究阶段的尿液生物标志物，如DNA甲基化、微卫星分析、miRNA等。本文就目前的尿液膀胱肿瘤标志物的研究进展作一综述。

关键词: 膀胱癌, 尿液肿瘤标志物, DNA甲基化, miRNA, 微卫星分析

Yang Libin, Xu Hanbiao. Research progress of urinary bladder tumor markers[J]. International Medicine and Health Guidance News, 2022, 28(20): 2898-2902.

杨礼宾许汉标. 尿液膀胱肿瘤标志物的研究进展[J]. 国际医药卫生导报, 2022, 28(20): 2898-2902.

References

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J].CA Cancer J Clin,2019,69(1):7-34.DOI:10.3322/caac.21551.
[2] van Rhijn BW, Burger M, Lotan Y, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy[J].Eur Urol,2009,56(3):430-442.DOI:10.1016/j.eururo.2009. 06.028.
[3] Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials[J].Eur Urol,2006,49(3):466-477. DOI:10.1016/j.eururo.2005.12.031.
[4] Piao XM, Jeong P, Kim YH, et al. Urinary cell-free microRNA biomarker could discriminate bladder cancer from benign hematuria[J].Int J Cancer,2019,144(2):380-388.DOI:10.1002/ijc.31849.
[5] Ponsky LE, Sharma S, Pandrangi L, et al. Screening and monitoring for bladder cancer: refining the use of NMP22[J].J Urol,2001,166(1):75-78.
[6] Comploj E, Mian C, Ambrosini-Spaltro A, et al. uCyt+/ImmunoCyt and cytology in the detection of urothelial carcinoma: an update on 7422 analyses[J].Cancer Cytopathol,2013,121(7):392-397.DOI:10.1002/cncy.21287.
[7] Laudadio J, Keane TE, Reeves HM, et al. Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice[J].BJU Int,2005,96(9):1280-1285.DOI:10.1111/j.1464- 410X.2005.05826.x.
[8] Glas AS, Roos D, Deutekom M, et al. Tumor markers in the diagnosis of primary bladder cancer. A systematic review[J].J Urol,2003,169(6):1975-1982.DOI:10.1097/01.ju.0000067461.30468.6d.
[9] Wang Z, Que H, Suo C, et al. Evaluation of the NMP22 BladderChek test for detecting bladder cancer: a systematic review and meta-analysis[J].Oncotarget,2017,8(59):100648-100656.DOI:10.18632/oncotarget.22065.
[10] Hajdinjak T. UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing[J].Urol Oncol,2008,26(6):646-651.DOI:10.1016/j.urolonc.2007.06.002.
[11] Chou R, Gore JL, Buckley D, et al. Urinary biomarkers for diagnosis of bladder cancer: z systematic review and meta-analysis[J].Ann Intern Med,2015,163(12):922-931.DOI:10.7326/M15-0997.
[12] Bubendorf L, Grilli B, Sauter G, et al. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings[J].Am J Clin Pathol,2001,116(1):79-86.DOI:10.1309/K5P2-4Y8B-7L5A-FAA9.
[13] Kamat AM, Willis DL, Dickstein RJ, et al. Novel fluorescence in situ hybridization-based definition of bacille Calmette-Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies[J].BJU Int,2016,117(5):754-760.DOI:10.1111/bju.13186.
[14] Kim JG, Takeshima H, Niwa T, et al. Comprehensive DNA methylation and extensive mutation analyses reveal an association between the CpG island methylator phenotype and oncogenic mutations in gastric cancers[J].Cancer Lett,2013,330(1):33-40.DOI:10.1016/j.canlet. 2012.11.022.
[15] Martinez VG, Munera-Maravilla E, Bernardini A, et al. Epigenetics of bladder cancer: where biomarkers and therapeutic targets meet[J].Front Genet,2019,10:1125.DOI:10.3389/fgene.2019.01125.
[16] Pu RT, Laitala LE, Clark DP. Methylation profiling of urothelial carcinoma in bladder biopsy and urine[J].Acta Cytol,2006,50(5):499-506.DOI:10.1159/000326003.
[17] Hauser S, Kogej M, Fechner G, et al. Serum DNA hypermethylation in patients with bladder cancer: results of a prospective multicenter study[J].Anticancer Res,2013,33(3):779-784.
[18] Renard I, Joniau S, van Cleynenbreugel B, et al. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples[J].Eur Urol,2010,58(1):96-104.DOI:10.1016/j.eururo.2009. 07.041.
[19] Fantony JJ, Longo TA, Gopalakrishna A, et al. Urinary NID2 and TWIST1 methylation to augment conventional urine cytology for the detection of bladder cancer[J].Cancer Biomark,2017,18(4):381-387.DOI:10.3233/CBM-160261.
[20] Wang Y, Yu Y, Ye R, et al. An epigenetic biomarker combination of PCDH17 and POU4F2 detects bladder cancer accurately by methylation analyses of urine sediment DNA in Han Chinese[J].Oncotarget,2016,7(3):2754-2764.DOI:10.18632/oncotarget.6666.
[21] van der Heijden AG, Mengual L, Ingelmo-Torres M, et al. Urine cell-based DNA methylation classifier for monitoring bladder cancer[J].Clin Epigenetics,2018,10:71.DOI:10.1186/s13148-018-0496-x.
[22] Lucca I, Hofbauer SL, Haitel A, et al. Urinary expression of genes involved in DNA methylation and histone modification for diagnosis of bladder cancer in patients with asymptomatic microscopic haematuria[J].Oncol Lett,2019,18(1):57-62.DOI:10.3892/ol.2019.10330.
[23] Su SF, de Castro Abreu AL, Chihara Y, et al. A panel of three markers hyper- and hypomethylated in urine sediments accurately predicts bladder cancer recurrence[J].Clin Cancer Res,2014,20(7):1978-1989.DOI:10.1158/1078-0432.CCR-13-2637.
[24] Roperch JP, Grandchamp B, Desgrandchamps F, et al. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer[J].BMC Cancer,2016,16(1):704.DOI:10.1186/s12885-016-2748-5.
[25] van Rhijn BW, Lurkin I, Kirkels WJ, et al. Microsatellite analysis--DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: a phase II trial[J].Cancer,2001,92(4):768-775.DOI:10.1002/1097-0142(20010815)92:4<768::aid-cncr1381>3.0.co;2-c
[26] Czerniak B, Chaturvedi V, Li L, et al. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer[J].Oncogene,1999,18(5):1185-1196.DOI:10.1038/sj.onc.1202385.
[27] Knowles MA, Elder PA, Williamson M, et al. Allelotype of human bladder cancer[J].Cancer Res,1994,54(2):531-538.
[28] Seripa D, Parrella P, Gallucci M, et al. Sensitive detection of transitional cell carcinoma of the bladder by microsatellite analysis of cells exfoliated in urine[J].Int J Cancer,2001,95(6):364-369.DOI:10.1002/1097- 0215(20011120)95:6<364::aid-ijc1064>3.0.co;2-v.
[29] Fendler A, Stephan C, Yousef GM, et al. The translational potential of microRNAs as biofluid markers of urological tumours[J].Nat Rev Urol,2016,13(12):734-752.DOI:10.1038/nrurol.2016.193.
[30] Kutwin P, Konecki T, Borkowska EM, et al. Urine miRNA as a potential biomarker for bladder cancer detection - a meta-analysis[J].Cent European J Urol,2018,71(2):177-185.DOI:10.5173/ceju.2018.1605.
[31] Kim SM, Kang HW, Kim WT, et al. Cell-free microRNA-214 from urine as a biomarker for non-muscle-invasive bladder cancer[J].Korean J Urol,2013,54(11):791-796.DOI:10.4111/kju.2013.54.11.791.
[32] Rivas A, Burzio V, Landerer E, et al. Determination of the differential expression of mitochondrial long non-coding RNAs as a noninvasive diagnosis of bladder cancer[J].BMC Urol,2012,12:37.DOI:10.1186/1471-2490-12-37.
[33] Derrien T, Johnson R, Bussotti G, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression[J].Genome Res,2012,22(9):1775-1789.DOI:10.1101/gr.132159.111.
[34] 张争,郝瀚,张崔建,等. 新基因UCA1用于膀胱癌诊断的临床应用价值[J]. 中华医学杂志,2012,92(6):384-387. DOI:10.3760/cma.j.issn.0376-2491.2012.06.008.
[35] 张本佳,詹晓曼,袁胜涛,等. LncRNA-UCA1在肿瘤转移中的研究进展[J]. 中国实验诊断学,2020,24(5):865-869. DOI:10.3969/j.issn.1007-4287.2020.05.044.
[36] Eissa S, Matboli M, Essawy NO, et al. Rapid detection of urinary long non-coding RNA urothelial carcinoma associated one using a PCR-free nanoparticle-based assay[J].Biomarkers,2015,20(3):212-217.DOI:10.3109/1354750X.2015.1062918.
[37] Gielchinsky I, Gilon M, Abu-Lail R, et al. H19 non-coding RNA in urine cells detects urothelial carcinoma: a pilot study[J].Biomarkers,2017,22(7):661-666.DOI:10.1080/1354750X.2016.1276625.
[38] Martens-Uzunova ES, Böttcher R, Croce CM, et al. Long noncoding RNA in prostate, bladder, and kidney cancer[J].Eur Urol,2014,65(6):1140-1151.DOI:10.1016/j.eururo.2013.12.003.
[39] Quan J, Pan X, Zhao L, et al. LncRNA as a diagnostic and prognostic biomarker in bladder cancer: a systematic review and meta-analysis[J].Onco Targets Ther,2018,11:6415-6424.DOI:10.2147/OTT.S167853.
[40] Wong YNS, Joshi K, Khetrapal P, et al. Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment[J].J Exp Med,2018,215(11):2748-2759.DOI:10.1084/jem.20181003.
[41] Salomo K, Huebner D, Boehme MU, et al. Urinary transcript quantitation of CK20 and IGF2 for the non-invasive bladder cancer detection[J].J Cancer Res Clin Oncol,2017,143(9):1757-1769. DOI:10.1007/s00432-017-2433-3.
[42] Shen C, Sun Z, Chen D, et al. Developing urinary metabolomic signatures as early bladder cancer diagnostic markers[J].OMICS,2015,19(1):1-11.DOI:10.1089/omi.2014.0116.